Tian Yu, Sohar Istvan, Taylor John W, Lobel Peter
Center for Advanced Biotechnology and Medicine, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA.
J Biol Chem. 2006 Mar 10;281(10):6559-72. doi: 10.1074/jbc.M507336200. Epub 2005 Dec 8.
Classical late-infantile neuronal ceroid lipofuscinosis is a fatal neurodegenerative disease caused by mutations in CLN2, the gene encoding the lysosomal protease tripeptidyl-peptidase I (TPP I). The natural substrates for TPP I and the pathophysiological processes associated with lysosomal storage and disease progression are not well understood. Detailed characterization of TPP I substrate specificity should provide insights into these issues and also aid in the development of improved clinical and biochemical assays. To this end, we constructed fluorogenic and standard combinatorial peptide libraries and analyzed them using fluorescence and mass spectrometry-based activity assays. The fluorogenic group 7-amino-4-carbamoylmethylcoumarin was incorporated into a series of 7-amino-4-carbamoylmethylcoumarin tripeptide libraries using a design strategy that allowed systematic evaluation of the P1, P2, and P3 positions. TPP I digestion of these substrates liberates the fluorescence group and results in a large increase in fluorescence that can be used to calculate kinetic parameters and to derive the substrate specificity constant kcat/KM. In addition, we implemented a mass spectrometry-based assay to measure the hydrolysis of individual peptides in peptide pools and thus expand the scope of the analysis. Nonfluorogenic tetrapeptide and pentapeptide libraries were synthesized and analyzed to evaluate P1' and P2' residues. Together, this analysis allowed us to predict the relative specificity of TPP I toward a wide range of potential biological substrates. In addition, we evaluated a variety of new fluorogenic peptides with a P3 Arg residue, and we demonstrated their superiority compared with the widely used substrate Ala-Ala-Phe-AMC for selectively measuring TPP I activity in biological specimens.
经典型晚发性婴儿神经元蜡样脂褐质沉积症是一种致命的神经退行性疾病,由CLN2基因突变引起,该基因编码溶酶体蛋白酶三肽基肽酶I(TPP I)。TPP I的天然底物以及与溶酶体储存和疾病进展相关的病理生理过程尚不清楚。对TPP I底物特异性的详细表征应有助于深入了解这些问题,并有助于开发改进的临床和生化检测方法。为此,我们构建了荧光和标准组合肽库,并使用基于荧光和质谱的活性检测方法对其进行分析。将荧光基团7-氨基-4-氨甲酰甲基香豆素通过一种设计策略掺入一系列7-氨基-4-氨甲酰甲基香豆素三肽库中,该策略允许对P1、P2和P3位置进行系统评估。这些底物经TPP I消化后释放出荧光基团,导致荧光大幅增加,可用于计算动力学参数并得出底物特异性常数kcat/KM。此外,我们实施了一种基于质谱的检测方法来测量肽库中单个肽的水解,从而扩大分析范围。合成并分析了非荧光四肽和五肽库,以评估P1'和P2'残基。通过这些分析,我们能够预测TPP I对多种潜在生物底物的相对特异性。此外,我们评估了多种带有P3精氨酸残基的新型荧光肽,并证明了它们与广泛使用的底物丙氨酸-丙氨酸-苯丙氨酸-7-氨基-4-甲基香豆素相比,在选择性测量生物样本中TPP I活性方面的优越性。